^
    Back
    Association details:
    Biomarker:HER-2 expression
    Cancer:Solid Tumor
    Drug:pertuzumab zuvotolimod (SBT6050) (HER2-targeted antibody-drug conjugate, TLR8 agonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors

    Excerpt:
    ...- Locally advanced or metastatic HER2-expressing (IHC 2+ or 3+) or amplified solid tumor...
    Trial ID:
    NCT04460456
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO 2021
    Title:

    209P - Interim results of a phase I/Ib study of SBT6050 monotherapy and pembrolizumab combination in patients with advanced HER2-expressing or amplified solid tumors

    Published date:
    09/13/2021
    Excerpt:
    Patients have HER2-expressing or -amplified solid tumors...In response-evaluable patients (N=14), best overall response was PR (n=1), SD (n=3), and PD (n=10)….Based on preliminary safety data, SBT6050 given alone or in combination with pembrolizumab has a manageable safety profile.
    Trial ID:
    NCT04460456